Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…
AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.
- CAR-PRISM results: compelling MRD negativity, potential treatment shift (4)
- Experts weigh in: praise, safety concerns, and clinical enthusiasm (4)
- Policy and IO context: regulation, immune engineering, industry implications (3)
- All Other Stories
CAR-PRISM results: compelling MRD negativity, potential treatment shift
Experts weigh in: praise, safety concerns, and clinical enthusiasm
Policy and IO context: regulation, immune engineering, industry implications
All Other Stories
Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma
Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …
AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.
Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC
oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]
AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.
- Experts on site: RAS inhibitors reshape NSCLC treatment landscape (5)
- Industry moves: BridgeBio reshuffles as KRAS race heats up (1)
- On the AACR floor: zoldonrasib delivers durable G12D responses (4)
- Perioperative and biomarker research reshapes precision care in NSCLC (4)
- All Other Stories